BRIEF published on 01/27/2025 at 22:20, 1 year 9 months ago Theralase's Interim Clinical Data to be Highlighted at 2025 AUA Annual Meeting Clinical Data Theralase Bladder Cancer Light-activated Therapy Urological Innovations
PRESS RELEASE published on 01/27/2025 at 22:15, 1 year 9 months ago Theralase(R) Interim Clinical Data to be Presented at the 2025 AUA Annual Meeting Theralase announces interim clinical data presentation at AUA Annual Meeting, showcasing promising results of light-activated Ruvidar™ in treating BCG-Unresponsive NMIBC CIS Theralase Bladder Cancer Interim Clinical Data Light-activated Ruvidar AUA Annual Meeting
BRIEF published on 12/09/2024 at 14:10, 1 year 11 months ago Theralase Expands Clinical Study Sites for Bladder Cancer Treatment in the U.S. Cancer Research Bladder Cancer Treatment Theralase Expansion Clinical Study Sites Ruvidar Activation
BRIEF published on 12/09/2024 at 14:10, 1 year 11 months ago Theralase élargit ses sites d'études cliniques pour le traitement du cancer de la vessie aux États-Unis Recherche Sur Le Cancer Expansion De La Théralase Traitement Du Cancer De La Vessie Sites D'études Cliniques Activation De Ruvidar
PRESS RELEASE published on 12/09/2024 at 14:05, 1 year 11 months ago Theralase(R) Launches Three New Clinical Study Sites in USA Theralase® launches new US Clinical Study Sites for bladder cancer treatment. Principal Investigators announced. Positive clinical data presented Clinical Data Theralase® Bladder Cancer US Clinical Study Sites
BRIEF published on 12/05/2024 at 13:05, 1 year 11 months ago Theralase Technologies Expands Bladder Cancer Study in Canada Canada Expansion Clinical Study Bladder Cancer Ruvidar Theralase Technologies
BRIEF published on 12/05/2024 at 13:05, 1 year 11 months ago Theralase Technologies étend son étude sur le cancer de la vessie au Canada Étude Clinique Cancer De La Vessie Ruvidar Technologies Théralase Expansion Au Canada
PRESS RELEASE published on 12/05/2024 at 13:00, 1 year 11 months ago Theralase(R) Launches New Clinical Study Site in Canada St. Joseph's Healthcare Hamilton joins Theralase®'s clinical investigation for bladder cancer treatment. Theralase® develops light-activated Ruvidar™ drug for BCG-Unresponsive NMIBC CIS patients Theralase® Bladder Cancer BCG-Unresponsive NMIBC CIS RuvidarTM Clinical Study Site
BRIEF published on 11/27/2024 at 23:10, 1 year 11 months ago Theralase publie son aperçu financier du troisième trimestre 2024 Placements Privés Dépenses De Recherche Et Développement Aperçu Financier De Theralase Chiffre D'affaires Et Marges Résultats De L'étude II
BRIEF published on 11/27/2024 at 23:10, 1 year 11 months ago Theralase Releases 3Q2024 Financial Overview Private Placements R&D Expenses Theralase Financial Overview Revenue And Margins Study II Results
Published on 11/20/2026 at 15:00, 17 hours 16 minutes ago Jaguar Health, Inc. Announces Reverse Stock Split
Published on 11/20/2026 at 14:50, 17 hours 26 minutes ago Proposed Issue Of Payment-In-Kind Interest Shares Under Convertible Debenture
Published on 11/20/2026 at 14:00, 18 hours 16 minutes ago Dateline appoints Tony Ferguson as Acting Chairman
Published on 11/20/2026 at 13:30, 18 hours 46 minutes ago Collective Metals Enters Into Option to Acquire the Lac Tio West Property in Quebec
Published on 11/20/2026 at 13:30, 18 hours 46 minutes ago Alset AI Closes Non-Brokered Private Placement Offering
Published on 11/20/2026 at 23:45, 8 hours 31 minutes ago APEC CEO Summit 2026 Concludes Successfully in Shenzhen
Published on 11/20/2026 at 22:39, 9 hours 36 minutes ago ABIVAX: Abivax publie une déclaration concernant le rapport d'un vendeur à découvert
Published on 11/20/2026 at 21:36, 10 hours 40 minutes ago EQS-Adhoc: Global Health Care AG: Board of Directors proposes sale of milon stake based on an equity value of EUR 23.3 million – subscription right for all shareholders
Published on 11/20/2026 at 20:49, 11 hours 27 minutes ago E-PANGO: Jugement du Tribunal Judiciaire de Paris relatif au contentieux avec le groupement RIVP-HENEO-HSF
Published on 11/20/2026 at 18:34, 13 hours 41 minutes ago Déclaration hebdomadaire d'opérations effectuées du 16 au 20 novembre 2026
Published on 11/20/2026 at 18:34, 13 hours 41 minutes ago Disclosure of transactions in own shares from November 16 to November 20, 2026
Published on 11/20/2026 at 17:35, 14 hours 41 minutes ago Guillemot Corporation S.A. | Déclaration hebdomadaire des transactions sur actions propres du 16 au 20 novembre 2026
Published on 11/20/2026 at 17:35, 14 hours 41 minutes ago Guillemot Corporation S.A. | Weekly report share buyback from November 16 to November 20, 2026
Published on 11/19/2026 at 19:00, 1 day 13 hours ago MR.BRICOLAGE: OUTLOOK FOR THE 2026 FINANCIAL YEAR